arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 3/2025 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    NEW ON THE MARKET

    Overactive bladder: vibegron (OBGEMSA) and what's new with mirabegron (BETMIGA)

    New indication: dupilumab (DUPIXENT) also for COPD

    THERAPY FROM A CRITICAL VIEWPOINT

    Interventional procedures for chronic back pain: benefit proven?

    a-t READERS QUESTIONS AND COMMENTS

    Low-dose naltrexone for fibromyalgia: what is the evidence?

    IN BRIEF

    Benzene in external acne treatment products containing benzoyl peroxide: batches recalled in the US
    free

    SIDE EFFECTS

    Heavy menstrual bleeding very common during anticoagulation

    Homicidal thoughts and serotonin syndrome with atomoxetine

    Non-steroidal anti-inflammatory drugs plus cholinesterase inhibitors: risk of peptic ulcer increased

    e a-t ON THE INTERNET

    New indication: dupilumab (DUPIXENT) also for COPD (long version)

    Addendum: misleading advertising for ORTOTON (methocarbamol)

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles

    Wir schätzen Ihr Feedback

    Nehmen Sie an unserer Umfrage teil!